Table 5. Hematologic toxicity in the carboplatin/paclitaxel group compared with hematologic toxicity reported from the CALGB 9781 clinical trial.
All data are reported as count (frequency).
*Indicates significant difference (Fisher’s exact p < 0.001).
| Carboplatin/Paclitaxel (Present Study) | Cisplatin/5-FU (CALGB 9781) | |||||
| Grade 3 | Grade 4 | Number of Patients Reporting | Grade 3 | Grade 4 | Number of Patients Reporting | |
| WBC | 30 (29) | 6 (6) | 103 | 7 (25) | 3 (11) | 28 |
| Granulocytes | 17 (17) | 3 (3) | 98 | 4 (15) | 3 (12) | 26 |
| Lymphocytes | 61 (59)* | 35 (34) | 103 | 2 (8)* | 10 (38) | 26 |
| Hemoglobin | 6 (6) | 3 (3) | 103 | 3 (11) | 1 (4) | 28 |
| Platelets | 6 (6) | 0 (0) | 103 | 2 (7) | 1 (4) | 27 |